|Bid||1.1400 x 3200|
|Ask||1.2000 x 1200|
|Day's Range||1.1000 - 1.2171|
|52 Week Range||0.2200 - 10.1500|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com. Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease. Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).